Alkermes Starts Phase 3 Study

Alkermes plc said pre-market Thursday that it has started a phase 3 study to evaluate the weight gain profile of ALKS 3831 compared to established atypical antipsychotic agent olanzapine in young adult patients with schizophrenia, schizophreniform or bipolar I disorder who are early in their illness.

The company said ALKS 3831 is designed to provide olanzapine’s strong antipsychotic efficacy and a differentiated safety profile with favorable weight and metabolic properties. “We believe that ALKS 3831 has the potential to have a meaningful impact on the treatment of schizophrenia, particularly in this young adult population that has demonstrated susceptibility to antipsychotic weight gain and who could benefit from a highly effective medicine early in the course of their disease,” CEO Richard Pops said.

Leave a Comment